Search

Your search keyword '"Radich, Jerald P."' showing total 1,427 results
Start Over Author "Radich, Jerald P."
1,427 results on '"Radich, Jerald P."'

1. Recommendations from the AML molecular MRD expert advisory board

Author

Scott, Stuart, Devonshire, Alison, Dillon, Richard, Thiede, Christian, Cross, Nicholas C. P., White, Helen E., Lo Cascio, Leandro, Mokretar, Katya, Potter, Nicola, Hourigan, Christopher S., Radich, Jerald, Corner, Adam, Laloux, Véronique, Halliday, Gemma, Dilks, Daniel, Morrison, Tom, Gilmour, Katelyn, Cartwright, Ashley, and Whitby, Liam

Published
2024
Full Text
View/download PDF

4. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Author

Garcia-Manero, Guillermo, Podoltsev, Nikolai A., Othus, Megan, Pagel, John M., Radich, Jerald P., Fang, Min, Rizzieri, David A., Marcucci, Guido, Strickland, Stephen A., Litzow, Mark R., Savoie, M. Lynn, Medeiros, Bruno C., Sekeres, Mikkael A., Lin, Tara L., Uy, Geoffrey L., Powell, Bayard L., Kolitz, Jonathan E., Larson, Richard A., Stone, Richard M., Claxton, David, Essell, James, Luger, Selina M., Mohan, Sanjay R., Moseley, Anna, Appelbaum, Frederick R., and Erba, Harry P.

Published
2024
Full Text
View/download PDF

6. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Author

Pogosova-Agadjanyan, Era L., Hua, Xing, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., Erba, Harry P., Fitzgibbon, Matthew P., Jenkins, Isaac C., Fang, Min, Lee, Stanley C., Moseley, Anna, Naru, Jasmine, Radich, Jerald P., Smith, Jenny L., Willborg, Brooke E., Willman, Cheryl L., Wu, Feinan, Meshinchi, Soheil, and Stirewalt, Derek L.

Published
2023
Full Text
View/download PDF

10. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis

Author

Zarnegar-Lumley, Sara, Alonzo, Todd A., Gerbing, Robert B., Othus, Megan, Sun, Zhuoxin, Ries, Rhonda E., Wang, Jim, Leonti, Amanda, Kutny, Matthew A., Ostronoff, Fabiana, Radich, Jerald P., Appelbaum, Frederick R., Pogosova-Agadjanyan, Era L., O’Dwyer, Kristen, Tallman, Martin S., Litzow, Mark, Atallah, Ehab, Cooper, Todd M., Aplenc, Richard A., Abdel-Wahab, Omar, Gamis, Alan S., Luger, Selina, Erba, Harry, Levine, Ross, Kolb, E. Anders, Stirewalt, Derek L., Meshinchi, Soheil, and Tarlock, Katherine

Published
2023
Full Text
View/download PDF

11. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021

Author

Mughal, Tariq I, Psaila, Bethan, DeAngelo, Daniel J, Saglio, Giuseppe, Van Etten, Richard A, and Radich, Jerald P

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Good Health and Well Being, Humans, Molecular Biology, Myeloproliferative Disorders, Neoplasms, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Published
2021

12. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies

Author

Mughal, Tariq I, Pemmaraju, Naveen, Psaila, Bethan, Radich, Jerald, Bose, Prithviraj, Lion, Thomas, Kiladjian, Jean‐Jacques, Rampal, Raajit, Jain, Tania, Verstovsek, Srdnan, Yacoub, Abdulraheem, Cortes, Jorge E, Mesa, Ruben, Saglio, Giuseppe, and Etten, Richard A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Rare Diseases, Orphan Drug, Cancer, Anemia, Biomarkers, Biomarkers, Tumor, Combined Modality Therapy, Disease Management, Disease Susceptibility, Drug Development, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Molecular Diagnostic Techniques, Molecular Targeted Therapy, Myeloproliferative Disorders, Prognosis, Single-Cell Analysis, Translational Research, Biomedical, Treatment Outcome, BCR-ABL1 mutants, genomic risk scores, interferon-alpha, luspatercept, non-JAK-STAT therapies, single-cell genomics, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single-cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis.

Published
2020

13. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis

Author

Kockerols, Camille, primary, Valk, Peter J. M., additional, Dulucq, Stéphanie, additional, Nicolini, Franck‐Emmanuel, additional, Mahon, François‐Xavier, additional, Atallah, Ehab, additional, Mauro, Michael J., additional, Radich, Jerald P., additional, Bernardi, Simona, additional, Russo, Domenico, additional, Farina, Mirko, additional, Mori, Silvia, additional, Gambacorti‐Passerini, Carlo, additional, Civettini, Ivan, additional, Lu, Liu, additional, Yeung, David, additional, Branford, Susan, additional, Colafigli, Gioia, additional, Breccia, Massimo, additional, Hogenbirk, Pauline, additional, van Rosmalen, Joost, additional, Cornelissen, Jan J., additional, and Westerweel, Peter E., additional

Published
2024
Full Text
View/download PDF

14. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Author

Short, Nicholas J, Jabbour, Elias, Albitar, Maher, de Lima, Marcos, Gore, Lia, Jorgensen, Jeffrey, Logan, Aaron C, Park, Jae, Ravandi, Farhad, Shah, Bijal, Radich, Jerald, and Kantarjian, Hagop

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pediatric Research Initiative, Rare Diseases, Hematology, Pediatric, Cancer, Childhood Leukemia, Pediatric Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Consensus, Guidelines as Topic, Humans, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, United States, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.

Published
2019

15. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Author

Atallah, Ehab, Schiffer, Charles A, Weinfurt, Kevin P, Zhang, Mei-Jie, Radich, Jerald P, Oehler, Vivian G, Pinilla-Ibarz, Javier, Deininger, Michael WN, Lin, Li, Larson, Richard A, Mauro, Michael J, Moore, Joseph O, Ritchie, Ellen K, Shah, Neil P, Silver, Richard T, Wadleigh, Martha, Cortes, Jorge, Thompson, James, Guhl, Jessica, Horowitz, Mary M, and Flynn, Kathryn E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Agents, Clinical Protocols, Fusion Proteins, bcr-abl, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Longitudinal Studies, Molecular Targeted Therapy, Patient Reported Outcome Measures, Protein Kinase Inhibitors, Quality of Life, Recurrence, Research Design, Watchful Waiting, Chronic myeloid leukemia, Oncology, Targeted therapy, Tyrosine kinase inhibitor, Discontinuation, Clinical trial, Study design, Patient-reported outcome, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BACKGROUND:Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life and very high cost. Several small studies from Europe and Australia suggested that discontinuing TKIs with regular monitoring was safe. METHODS:The Life After Stopping TKIs (LAST) study is a large, U.S.-based study that aims to improve the evidence for clinical decision making regarding TKI discontinuation with monitoring in patients with chronic myeloid leukemia who have a deep molecular response to TKI therapy. The LAST study is a non-randomized, prospective, single-group longitudinal study of 173 patients. The co-primary objectives are to determine the proportion of patients who develop molecular recurrence (> 0.1% BCR-ABLIS) after discontinuing one of four TKIs (imatinib, dasatinib, nilotinib, or bosutinib) and to compare the patient-reported health status of patients before and after stopping TKIs. Outcomes are assessed at baseline and throughout the 36-month study follow-up period with a central laboratory used for blood samples. All samples with undetectable BCR-ABL are also examined using digital polymerase chain reaction, which is a more sensitive nanofluidic polymerase chain reaction system. DISCUSSION:Because of their high cost and side effects, discontinuation of TKIs for patients with chronic myeloid leukemia who have a deep molecular response to TKI therapy is a promising approach to treatment. The LAST study is the largest U.S.-based TKI discontinuation study. It is the first to allow participation from patients on any of 4 first- and second-generation TKIs, includes a robust approach to measurement of clinical and patient-reported outcomes, and is using digital polymerase chain reaction to explore better prediction of safe discontinuation. TRIAL REGISTRATION:This study was registered prospectively on October 21, 2014 and assigned trial number NCT02269267 .

Published
2018

16. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Author

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert P., Borowitz, Michael J., Calvo, Katherine R., Kvasnicka, Hans-Michael, Wang, Sa A., Bagg, Adam, Barbui, Tiziano, Branford, Susan, Bueso-Ramos, Carlos E., Cortes, Jorge E., Dal Cin, Paola, DiNardo, Courtney D., Dombret, Hervé, Duncavage, Eric J., Ebert, Benjamin L., Estey, Elihu H., Facchetti, Fabio, Foucar, Kathryn, Gangat, Naseema, Gianelli, Umberto, Godley, Lucy A., Gökbuget, Nicola, Gotlib, Jason, Hellström-Lindberg, Eva, Hobbs, Gabriela S., Hoffman, Ronald, Jabbour, Elias J., Kiladjian, Jean-Jacques, Larson, Richard A., Le Beau, Michelle M., Loh, Mignon L.-C., Löwenberg, Bob, Macintyre, Elizabeth, Malcovati, Luca, Mullighan, Charles G., Niemeyer, Charlotte, Odenike, Olatoyosi M., Ogawa, Seishi, Orfao, Alberto, Papaemmanuil, Elli, Passamonti, Francesco, Porkka, Kimmo, Pui, Ching-Hon, Radich, Jerald P., Reiter, Andreas, Rozman, Maria, Rudelius, Martina, Savona, Michael R., Schiffer, Charles A., Schmitt-Graeff, Annette, Shimamura, Akiko, Sierra, Jorge, Stock, Wendy A., Stone, Richard M., Tallman, Martin S., Thiele, Jürgen, Tien, Hwei-Fang, Tzankov, Alexandar, Vannucchi, Alessandro M., Vyas, Paresh, Wei, Andrew H., Weinberg, Olga K., Wierzbowska, Agnieszka, Cazzola, Mario, Döhner, Hartmut, and Tefferi, Ayalew

Published
2022
Full Text
View/download PDF

18. MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis

Author

Zhao, Helong, Pomicter, Anthony D., Eiring, Anna M., Franzini, Anca, Ahmann, Jonathan, Hwang, Jae-Yeon, Senina, Anna, Helton, Bret, Iyer, Siddharth, Yan, Dongqing, Khorashad, Jamshid S., Zabriskie, Matthew S., Agarwal, Anupriya, Redwine, Hannah M., Bowler, Amber D., Clair, Phillip M., McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Stirewalt, Derek L., Oehler, Vivian G., Varambally, Sooryanarayana, Berrett, Kristofer C., Vahrenkamp, Jeffery M., Gertz, Jason, Varley, Katherine E., Radich, Jerald P., and Deininger, Michael W.

Published
2022
Full Text
View/download PDF

19. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms

Author

Mughal, Tariq I, Gotlib, Jason, Mesa, Ruben, Koschmieder, Steffen, Khoury, H Jean, Cortes, Jorge E, Barbui, Tiziano, Hehlmann, Rüdiger, Mauro, Michael, Saussele, Susanne, Radich, Jerald P, Van Etten, Richard A, Saglio, Giuseppe, Verstovek, Srdnan, Gale, Robert Peter, and Abdel-Wahab, Omar

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Hematology, Good Health and Well Being, Antineoplastic Agents, Calreticulin, Cardiovascular Diseases, Cell Transformation, Neoplastic, Chronic Disease, Congresses as Topic, Epigenesis, Genetic, Fusion Proteins, bcr-abl, Humans, Janus Kinase 2, Mastocytosis, Systemic, Mutation, Myeloproliferative Disorders, Protein Kinase Inhibitors, Remission Induction, Staurosporine, Translational Research, Biomedical, CML, MPN, TFR, Mastocytosis, CALR, Cardiotoxicity, JAK2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

Published
2018

20. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Author

Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, and Saglio, Giuseppe

Published
2021
Full Text
View/download PDF

21. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Author

Forman, Stephen, Ha, Chul, Wong, Jeffrey, Tallman, Martin, Paietta, Elisabeth, Racevskis, Janis, Uy, Geoffrey, Horowitz, Mary, Takebe, Naoko, Little, Richard, Borate, Uma, Kebriaei, Partow, Kingsbury, Laura, Kantarjian, Hagop, Radich, Jerald, Erba, Harry, Appelbaum, Frederick, Ravandi, Farhad, Othus, Megan, and OBrien, Susan

Abstract

This multicenter trial was conducted to determine whether the addition of dasatinib to chemotherapy followed by an allogeneic hematopoietic cell transplant (HCT) in patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was feasible. Patients ≥ 18 and ≤ 60 years of age with newly diagnosed Ph+ ALL received up to 8 cycles of alternating hyperCVAD and high dose cytarabine and methotrexate with dasatinib. Patients with an available matched sibling or unrelated donor underwent an allogeneic HCT in first complete remission (CR1) followed by daily dasatinib starting from day 100. Others received maintenance therapy with vincristine and prednisone for 2 years and dasatinib indefinitely. 97 patients (94 evaluable) with median age of 44 years (range, 20 - 60) and median WBC at presentation of 10 × 109/L (range, 1 - 410 × 109/L) were accrued. 83 (88%) patients achieved CR or CR with incomplete count recovery (CRi) and 41 underwent ASCT in CR1. Median follow-up is 36 months (range, 9 - 63). For the overall population, overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) at 3 years were 69%, 55%, and 62%, respectively. The 12-month RFS and OS after transplant were 71% and 87%, respectively. Landmark analysis at 175 days from the time of CR/CRi (longest time to HCT), showed statistically superior advantages for RFS and OS (p=0.038 and 0.037, respectively) for the transplanted patients. Addition of dasatinib to chemotherapy and HCT for younger patients with Ph+ ALL is feasible and warrants further testing.

Published
2016

22. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Author

Ravandi, Farhad, Othus, Megan, O'Brien, Susan M, Forman, Stephen J, Ha, Chul S, Wong, Jeffrey YC, Tallman, Martin S, Paietta, Elisabeth, Racevskis, Janis, Uy, Geoffrey L, Horowitz, Mary, Takebe, Naoko, Little, Richard, Borate, Uma, Kebriaei, Partow, Kingsbury, Laura, Kantarjian, Hagop M, Radich, Jerald P, Erba, Harry P, and Appelbaum, Frederick R

Subjects
Pediatric, Pediatric Cancer, Cancer, Hematology, Transplantation, Stem Cell Research, Childhood Leukemia, Rare Diseases, Clinical Research
Abstract

This multicenter trial was conducted to determine whether the addition of dasatinib to chemotherapy followed by an allogeneic hematopoietic cell transplant (HCT) in patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was feasible. Patients ≥ 18 and ≤ 60 years of age with newly diagnosed Ph+ ALL received up to 8 cycles of alternating hyperCVAD and high dose cytarabine and methotrexate with dasatinib. Patients with an available matched sibling or unrelated donor underwent an allogeneic HCT in first complete remission (CR1) followed by daily dasatinib starting from day 100. Others received maintenance therapy with vincristine and prednisone for 2 years and dasatinib indefinitely. 97 patients (94 evaluable) with median age of 44 years (range, 20 - 60) and median WBC at presentation of 10 × 109/L (range, 1 - 410 × 109/L) were accrued. 83 (88%) patients achieved CR or CR with incomplete count recovery (CRi) and 41 underwent ASCT in CR1. Median follow-up is 36 months (range, 9 - 63). For the overall population, overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) at 3 years were 69%, 55%, and 62%, respectively. The 12-month RFS and OS after transplant were 71% and 87%, respectively. Landmark analysis at 175 days from the time of CR/CRi (longest time to HCT), showed statistically superior advantages for RFS and OS (p=0.038 and 0.037, respectively) for the transplanted patients. Addition of dasatinib to chemotherapy and HCT for younger patients with Ph+ ALL is feasible and warrants further testing.

Published
2016

23. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Author

Gu, Zhaohui, Churchman, Michelle, Roberts, Kathryn, Li, Yongjin, Liu, Yu, Harvey, Richard C, McCastlain, Kelly, Reshmi, Shalini C, Payne-Turner, Debbie, Iacobucci, Ilaria, Shao, Ying, Chen, I-Ming, Valentine, Marcus, Pei, Deqing, Mungall, Karen L, Mungall, Andrew J, Ma, Yussanne, Moore, Richard, Marra, Marco, Stonerock, Eileen, Gastier-Foster, Julie M, Devidas, Meenakshi, Dai, Yunfeng, Wood, Brent, Borowitz, Michael, Larsen, Eric E, Maloney, Kelly, Mattano, Leonard A, Angiolillo, Anne, Salzer, Wanda L, Burke, Michael J, Gianni, Francesca, Spinelli, Orietta, Radich, Jerald P, Minden, Mark D, Moorman, Anthony V, Patel, Bella, Fielding, Adele K, Rowe, Jacob M, Luger, Selina M, Bhatia, Ravi, Aldoss, Ibrahim, Forman, Stephen J, Kohlschmidt, Jessica, Mrózek, Krzysztof, Marcucci, Guido, Bloomfield, Clara D, Stock, Wendy, Kornblau, Steven, Kantarjian, Hagop M, Konopleva, Marina, Paietta, Elisabeth, Willman, Cheryl L, Loh, Mignon L, Hunger, Stephen P, and Mullighan, Charles G

Subjects
NIH 3T3 Cells, Animals, Humans, Mice, Luciferases, Oncogene Proteins, Fusion, Treatment Outcome, Sequence Analysis, RNA, Genomics, Gene Expression Regulation, Leukemic, Gene Rearrangement, Base Sequence, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Histone Deacetylase Inhibitors, Transcriptome, MEF2 Transcription Factors, Genetics, Pediatric Cancer, Cancer, Pediatric, 2.1 Biological and endogenous factors
Abstract

Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here using RNA sequencing of 560 ALL cases, we identify rearrangements between MEF2D (myocyte enhancer factor 2D) and five genes (BCL9, CSF1R, DAZAP1, HNRNPUL1 and SS18) in 22 B progenitor ALL (B-ALL) cases with a distinct gene expression profile, the most common of which is MEF2D-BCL9. Examination of an extended cohort of 1,164 B-ALL cases identified 30 cases with MEF2D rearrangements, which include an additional fusion partner, FOXJ2; thus, MEF2D-rearranged cases comprise 5.3% of cases lacking recurring alterations. MEF2D-rearranged ALL is characterized by a distinct immunophenotype, DNA copy number alterations at the rearrangement sites, older diagnosis age and poor outcome. The rearrangements result in enhanced MEF2D transcriptional activity, lymphoid transformation, activation of HDAC9 expression and sensitive to histone deacetylase inhibitor treatment. Thus, MEF2D-rearranged ALL represents a distinct form of high-risk leukaemia, for which new therapeutic approaches should be considered.

Published
2016

24. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Author

Mulé, Matthew P, Mannis, Gabriel N, Wood, Brent L, Radich, Jerald P, Hwang, Jimmy, Ramos, Nestor R, Andreadis, Charalambos, Damon, Lloyd, Logan, Aaron C, Martin, Thomas G, and Hourigan, Christopher S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Transplantation, Genetics, Pediatric Cancer, Cancer, Childhood Leukemia, Clinical Research, Hematology, Pediatric, Rare Diseases, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Adult, Aged, Autografts, Female, Flow Cytometry, Genes, Wilms Tumor, Hematopoietic Stem Cell Transplantation, Humans, Leukapheresis, Leukemia, Myeloid, Acute, Male, Middle Aged, Neoplasm, Residual, Polymerase Chain Reaction, Predictive Value of Tests, Recurrence, Retrospective Studies, Risk Assessment, Specimen Handling, Transplantation, Autologous, Young Adult, Acute myeloid leukemia, Autologous hematopoietic cell transplantation, Measurable residual disease, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We report here the largest study to date of adult patients with acute myeloid leukemia (AML) tested for measurable residual disease (MRD) at the time of autologous hematopoietic cell transplantation (auto-HCT). Seventy-two adult patients who underwent transplantation between 2004 and 2013 at a single academic medical center (University of California San Francisco) were eligible for this retrospective study based on availability of cryopreserved granulocyte colony-stimulating factor (GCSF)-mobilized autologous peripheral blood progenitor cell (PBPC) leukapheresis specimens ("autografts"). Autograft MRD was assessed by molecular methods (real-time quantitative PCR [RQ-PCR] for Wilms tumor 1 (WT1) alone or a multigene panel) and by multiparameter flow cytometry (MPFC). WT1 RQ-PCR testing of the autograft had low sensitivity for relapse prediction (14%) and a negative predictive value of 51%. MPFC failed to identify MRD in any of 34 autografts tested. Combinations of molecular MRD assays, however, improved prediction of post-auto-HCT relapse. In multivariate analysis of clinical variables, including age, gender, race, cytogenetic risk category, and CD34+ cell dose, only autograft multigene MRD as assessed by RQ-PCR was statistically significantly associated with relapse. One year after transplantation, only 28% patients with detectable autograft MRD were relapse free, compared with 67% in the MRD-negative cohort. Multigene MRD, while an improvement on other methods tested, was however suboptimal for relapse prediction in unselected patients, with specificity of 83% and sensitivity of 46%. In patients with known chromosomal abnormalities or mutations, however, better predictive value was observed with no relapses observed in MRD-negative patients in the first year after auto-HCT compared with 83% incidence of relapse in the MRD-positive patients (hazard ratio, 12.45; P = .0016). In summary, increased personalization of MRD monitoring by use of a multigene panel improved the ability to risk stratify patients for post-auto-HCT relapse. WT1 RQ-PCR and flow cytometric assessment for AML MRD in autograft samples had limited value for predicting relapse after auto-HCT. We demonstrate that cryopreserved autograft material presents unique challenges for AML MRD testing because of the masking effects of previous GCSF exposure on gene expression and flow cytometry signatures. In the absence of information regarding diagnostic characteristics, sources other than GCSF-stimulated PBSC leukapheresis specimens should be considered as alternatives for MRD testing in AML patients undergoing auto-HCT.

Published
2016

27. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Author

Garcia-Manero, Guillermo, primary, Podoltsev, Nikolai A., additional, Othus, Megan, additional, Pagel, John M., additional, Radich, Jerald P., additional, Fang, Min, additional, Rizzieri, David A., additional, Marcucci, Guido, additional, Strickland, Stephen A., additional, Litzow, Mark R., additional, Savoie, M. Lynn, additional, Medeiros, Bruno C., additional, Sekeres, Mikkael A., additional, Lin, Tara L., additional, Uy, Geoffrey L., additional, Powell, Bayard L., additional, Kolitz, Jonathan E., additional, Larson, Richard A., additional, Stone, Richard M., additional, Claxton, David, additional, Essell, James, additional, Luger, Selina M., additional, Mohan, Sanjay R., additional, Moseley, Anna, additional, Appelbaum, Frederick R., additional, and Erba, Harry P., additional

Published
2023
Full Text
View/download PDF

31. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

33. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Author

Dillon, Laura W., primary, Higgins, Jake, additional, Nasif, Hassan, additional, Othus, Megan, additional, Beppu, Lan, additional, Smith, Thomas H., additional, Schmidt, Elizabeth, additional, Valentine III, Charles C., additional, Salk, Jesse J., additional, Wood, Brent L, additional, Erba, Harry P., additional, Radich, Jerald P., additional, and Hourigan, Christopher S., additional

Published
2023
Full Text
View/download PDF

36. Chronic Myelogenous Leukemia, Version 1.2014.

Author

O'Brien, Susan, Radich, Jerald P, Abboud, Camille N, Akhtari, Mojtaba, Altman, Jessica K, Berman, Ellin, DeAngelo, Daniel J, Deininger, Michael, Devine, Steven, Fathi, Amir T, Gotlib, Jason, Jagasia, Madan, Kropf, Patricia, Moore, Joseph O, Pallera, Arnel, Pinilla-Ibarz, Javier, Reddy, Vishnu Vb, Shah, Neil P, Smith, B Douglas, Snyder, David S, Wetzler, Meir, Gregory, Kristina, and Sundar, Hema

Subjects
Pediatric, Cancer, Hematology, Rare Diseases, Orphan Drug, Pediatric Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Fusion Proteins, bcr-abl, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Prognosis, Protein Kinase Inhibitors, Ntational comprehensive cancer network, Oncology & Carcinogenesis
Abstract

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

Published
2013

42. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.

Author

Van Etten, Richard A, Mauro, Michael, Radich, Jerald P, Goldman, John M, Saglio, Giuseppe, Jamieson, Catriona, Soverini, Simona, Gambacorti-Passerini, Carlo, Hehlmann, Rüdiger, Martinelli, Giovanni, Perrotti, Danilo, Scadden, David T, Skorski, Tomasz, Tefferi, Ayalew, and Mughal, Tariq I

Subjects
Animals, Antineoplastic Agents: therapeutic use, Genomics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive: etiology, therapy, Molecular Targeted Therapy, Neoplastic Stem Cells: metabolism, Protein Kinase Inhibitors: therapeutic use, Stem Cell Niche, Treatment Outcome
Abstract

Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.

Published
2013

43. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Author

Gu, Zhaohui, Churchman, Michelle L., Roberts, Kathryn G., Moore, Ian, Zhou, Xin, Nakitandwe, Joy, Hagiwara, Kohei, Pelletier, Stephane, Gingras, Sebastien, Berns, Hartmut, Payne-Turner, Debbie, Hill, Ashley, Iacobucci, Ilaria, Shi, Lei, Pounds, Stanley, Cheng, Cheng, Pei, Deqing, Qu, Chunxu, Newman, Scott, Devidas, Meenakshi, Dai, Yunfeng, Reshmi, Shalini C., Gastier-Foster, Julie, Raetz, Elizabeth A., Borowitz, Michael J., Wood, Brent L., Carroll, William L., Zweidler-McKay, Patrick A., Rabin, Karen R., Mattano, Leonard A., Maloney, Kelly W., Rambaldi, Alessandro, Spinelli, Orietta, Radich, Jerald P., Minden, Mark D., Rowe, Jacob M., Luger, Selina, Litzow, Mark R., Tallman, Martin S., Racevskis, Janis, Zhang, Yanming, Bhatia, Ravi, Kohlschmidt, Jessica, Mrózek, Krzysztof, Bloomfield, Clara D., Stock, Wendy, Kornblau, Steven, Kantarjian, Hagop M., Konopleva, Marina, Evans, Williams E., Jeha, Sima, Pui, Ching-Hon, Yang, Jun, Paietta, Elisabeth, Downing, James R., Relling, Mary V., Zhang, Jinghui, Loh, Mignon L., Hunger, Stephen P., and Mullighan, Charles G.

Published
2019
Full Text
View/download PDF

44. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Author

Pogosova-Agadjanyan, Era L., Moseley, Anna, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., Chen, I-Ming L., Erba, Harry P., Godwin, John E., Jenkins, Isaac C., Fang, Min, Huynh, Mike, Kopecky, Kenneth J., List, Alan F., Naru, Jasmine, Radich, Jerald P., Stevens, Emily, Willborg, Brooke E., Willman, Cheryl L., Wood, Brent L., Zhang, Qing, Meshinchi, Soheil, and Stirewalt, Derek L.

Published
2020
Full Text
View/download PDF

45. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Author

Mughal, Tariq I, Radich, Jerald P, Van Etten, Richard A, Quintás-Cardama, Alfonso, Skorski, Tomasz, Ravandi, Farhad, DeAngelo, Daniel J, Gambacorti-Passerini, Carlo, Martinelli, Giovanni, and Tefferi, Ayalew

Subjects
Animals, Antineoplastic Agents: therapeutic use, Drug Monitoring, Drug Resistance, Neoplasm, Genomic Instability, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive: drug therapy, genetics, therapy, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative: drug therapy, genetics, therapy, alanine aminotransferase, BCR ABL protein, bosutinib, cytarabine, dasatinib, dcc 2036, imatinib, methotrexate, nilotinib, pha 739258, ponatinib, prednisone, unclassified drug, vincristine, acute lymphoblastic leukemia, alanine aminotransferase blood level, anemia, bone pain, cancer classification, cancer patient, cancer relapse, cancer survival, chronic myeloid leukemia, conference paper, consensus development, diarrhea, disease course, drug dose escalation, drug efficacy, drug eruption, drug megadose, drug safety, drug withdrawal, follow up, gene, gene expression, gene mutation, genetics, genomic instability, human, hypermagnesemia, in vitro study, leukemia progenitor cell, multiple cycle treatment, muscle cramp, nausea and vomiting, neutropenia, pancreatitis, periorbital edema, phenotype, Philadelphia chromosome positive cell, pleura effusion, polymerase chain reaction, priority journal, side effect, signal transduction, single nucleotide polymorphism, stem cell, thrombocytopenia, Animals, Antineoplastic Agents, Drug Monitoring, Drug Resistance, Neoplasm, Genomic Instability, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Published
2011

46. Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Author

Termini, Christina M., primary, Moseley, Anna, additional, Othus, Megan, additional, Appelbaum, Frederick R., additional, Chauncey, Thomas R., additional, Erba, Harry P., additional, Fang, Min, additional, Lee, Stanley C., additional, Naru, Jasmine, additional, Pogosova-Agadjanyan, Era L., additional, Radich, Jerald P., additional, Willman, Cheryl L., additional, Wu, Feinan, additional, Meshinchi, Soheil, additional, and Stirewalt, Derek L., additional

Published
2023
Full Text
View/download PDF

48. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Author

Short, Nicholas J., Kantarjian, Hagop, Kanagal-Shamanna, Rashmi, Sasaki, Koji, Ravandi, Farhad, Cortes, Jorge, Konopleva, Marina, Issa, Ghayas C., Kornblau, Steven M., Garcia-Manero, Guillermo, Garris, Rebecca, Higgins, Jake, Pratt, Gabriel, Williams, Lindsey N., Valentine, III, Charles C., Rivera, Victor M., Pritchard, Justin, Salk, Jesse J., Radich, Jerald, and Jabbour, Elias

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results